Amicus Therapeutics, Inc. (NASDAQ:FOLD) Position Increased by Mesirow Institutional Investment Management Inc.

Mesirow Institutional Investment Management Inc. grew its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 9.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 89,382 shares of the biopharmaceutical company’s stock after acquiring an additional 7,630 shares during the period. Mesirow Institutional Investment Management Inc.’s holdings in Amicus Therapeutics were worth $842,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of FOLD. Vanguard Group Inc. lifted its position in Amicus Therapeutics by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company’s stock worth $275,619,000 after acquiring an additional 458,143 shares during the last quarter. Wellington Management Group LLP boosted its stake in Amicus Therapeutics by 18.8% during the 4th quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company’s stock valued at $268,112,000 after purchasing an additional 4,497,950 shares during the period. Geode Capital Management LLC boosted its stake in Amicus Therapeutics by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company’s stock valued at $70,499,000 after purchasing an additional 80,926 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in Amicus Therapeutics by 3.4% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 3,267,375 shares of the biopharmaceutical company’s stock valued at $30,779,000 after buying an additional 107,348 shares during the last quarter. Finally, Norges Bank bought a new position in Amicus Therapeutics in the 4th quarter worth approximately $29,033,000.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD opened at $6.83 on Monday. The stock has a market capitalization of $2.10 billion, a P/E ratio of -37.94, a price-to-earnings-growth ratio of 1.51 and a beta of 0.79. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a 1 year low of $6.20 and a 1 year high of $12.65. The firm has a 50 day moving average of $8.42 and a 200-day moving average of $9.51.

Wall Street Analysts Forecast Growth

FOLD has been the topic of a number of research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Wells Fargo & Company decreased their target price on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, January 15th. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $16.75.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.